Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

KWALITY PHARMACEUTICALS LTD.

NSE : NABSE : 539997ISIN CODE : INE552U01010Industry : Pharmaceuticals & DrugsHouse : Private

BSE1431.2069.2 (+5.08 %)

PREV CLOSE ( ) 1362.00

OPEN PRICE ( ) 1388.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 182350

TODAY'S LOW / HIGH ( )1321.10 1456.00

52 WK LOW / HIGH ( ) 596.051456

NSE

This Company is not listed in NSE

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 04-05 1983

Management Info

- Chairman Ramesh Kumar - Managing Director

Registered Office

Address 6th Mile Stone,Village Nagkalan,Majitha Road,
Amritsar,
Punjab-143601

Phone 08558820862 / 63 / 9915743720

Email export@kwalitypharma.com / ramesh@kwalitypharma.com

Website www.kwalitypharma.com

Registrars Details

Bigshare Services Pvt Ltd

Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai

Listing : BSE

NEWS

02Feb Kwality Pharmaceuticals informs about
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosur..

14Jan Kwality Pharmaceuticals informs about
Kwality Pharmaceuticals has informed that it enclosed confirmation certi..

01Jan Appointment of Director
Inter alia, considered and approved the appointment of Mr. PreetMohinder..

06Nov Kwality Pharmaceuticals informs about
Kwality Pharmaceuticals has informed regarding the successful completion..

18Aug Kwality Pharmaceuticals gets registrat
Kwality Pharmaceutical has received registration for Bleomycin 15 IU in..

Financials

Rs. in Millions

	QTR Dec 25	ANNUAL 25
Net Profit	160.06	398.9
Gross Profit	223.52	542.28
Operating Profit	304.81	823.64
Net Sales	1234.45	3701.97

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 13043.80 (0.65%)	M.Cap ( in Cr)16735.05
Sanofi Cons. Health (BSE) 4299.65 (1.54%)	M.Cap ( in Cr)9902.36
Astrazeneca Pharma I (BSE) 8878.75 (0.59%)	M.Cap ( in Cr)22196.88
NGL Fine-Chem (BSE) 2291.65 (2.29%)	M.Cap ( in Cr)1415.79
Haleos Labs (BSE) 1355.75 (3.19%)	M.Cap ( in Cr)409.88

Shareholding Pattern

	PROMOTERS	54.83%
	NON-INSTITUTION	44.34%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

KWALITY PHARMACEUTICALS LTD.